within Pharmacolibrary.Drugs.S_SensoryOrgans.S01G_DecongestantsAndAntiallergics.S01GX13_Bilastine;

model Bilastine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.606,
    Cl = 7.583333333333334e-06,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0012900000000000001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.015000000000000001,
    Tlag = 10.200000000000001,
    Vdp = 0.0005899999999999999,
    k12 = 4.8611111111111105e-06,
    k21 = 4.8611111111111105e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Bilastine</td></tr><tr><td>ATC code:</td><td>S01GX13</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.29</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.39</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Bilastine is a second-generation non-sedating antihistamine used for the treatment of allergic rhinoconjunctivitis and urticaria in adults and children over 12 years; it is approved and in clinical use today in Europe and other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration of bilastine 20 mg as a single dose, under fasting conditions.</p><h4>References</h4><ol><li><p>Togawa, M, et al., &amp; Nagashima, H (2016). Pharmacokinetics, Pharmacodynamics and Population Pharmacokinetic/Pharmacodynamic Modelling of Bilastine, a Second-Generation Antihistamine, in Healthy Japanese Subjects. <i>Clinical drug investigation</i> 36(12) 1011–1021. DOI:<a href=\"https://doi.org/10.1007/s40261-016-0447-2\">10.1007/s40261-016-0447-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27498100/\">https://pubmed.ncbi.nlm.nih.gov/27498100</a></p></li><li><p>Vozmediano, V, et al., &amp; Rodriguez, M (2019). Model-informed pediatric development applied to bilastine: Analysis of the clinical PK data and confirmation of the dose selected for the target population. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 128 180–192. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2018.11.016\">10.1016/j.ejps.2018.11.016</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30468868/\">https://pubmed.ncbi.nlm.nih.gov/30468868</a></p></li><li><p>Novák, Z, et al., &amp; Valiente, R (2016). Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. <i>Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology</i> 27(5) 493–498. DOI:<a href=\"https://doi.org/10.1111/pai.12555\">10.1111/pai.12555</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26918853/\">https://pubmed.ncbi.nlm.nih.gov/26918853</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01GX13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Bilastine;
